Genocea Biosciences Inc (NASDAQ:GNCA) shares traded down 5.1% during trading on Friday . The company traded as low as $0.90 and last traded at $0.93. 1,768,341 shares traded hands during mid-day trading, an increase of 36% from the average session volume of 1,300,616 shares. The stock had previously closed at $0.98.

A number of research analysts recently commented on the company. Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Tuesday. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 price target on shares of Genocea Biosciences in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.45.

The firm has a market cap of $76.32, a price-to-earnings ratio of -0.43 and a beta of 1.55. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55.

Several institutional investors and hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. raised its holdings in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 2,300 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Genocea Biosciences during the 2nd quarter worth approximately $100,000. Rhumbline Advisers purchased a new stake in shares of Genocea Biosciences during the 2nd quarter worth approximately $157,000. New York State Common Retirement Fund purchased a new stake in shares of Genocea Biosciences during the 2nd quarter worth approximately $159,000. Finally, OxFORD Asset Management LLP purchased a new stake in shares of Genocea Biosciences during the 2nd quarter worth approximately $204,000. 12.02% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/02/09/genocea-biosciences-gnca-shares-down-5-1.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.